Mammary Cell News Volume 11.37 | Sep 26 2019

TOP STORY

S100A4 Released from Highly Bone-Metastatic Breast Cancer Cells Plays a Critical Role in Osteolysis

To identify soluble factors released from cancer cells in bone metastasis, the authors established a highly bone-metastatic subline of MDA-MB-231 breast cancer cells. [Bone Res] Full Article

(Ranked by impact factor of the journal)

NLRP3 Inflammasome in Fibroblasts Links Tissue Damage with Inflammation in Breast Cancer Progression and Metastasis

Scientists found that fibroblasts sensed damage-associated molecular patterns, and in response activated the NLRP3 inflammasome pathway, resulting in instigation of pro-inflammatory signaling and secretion of IL-1β. This upregulation was evident in cancer-associated fibroblasts in mouse and in human breast carcinomas. [Nat Commun] Full Article

The FBXW2-MSX2-SOX2 Axis Regulates Stem Cell Property and Drug Resistance of Cancer Cells

By down-regulating SOX2 through inactivation of FBXW2 E3 ligase, MLN4924 sensitized breast cancer cells to tamoxifen in both in vitro and in vivo cancer cell models. [Proc Natl Acad Sci USA] Abstract

GLS2 Is Protumorigenic in Breast Cancers

Despite having high glutaminase 1 (GLS) levels, investigators verified that several breast cancer cells expressed endogenous GLS2, defying its role as a bona fide tumor suppressor. [Oncogene] Abstract

SEPT9_i1 Regulates Human Breast Cancer Cell Motility through Cytoskeletal and RhoA/FAK Signaling Pathway Regulation

Lentivirus-mediated shRNA knockdown of SEPT9 in MCF-7 cells diminished tumor cell migration, focal adhesion (FA) maturation and the expression of β-actin, β-tubulin, Cdc42, RhoA, and Rac, whereas overexpression of SEPT9_i1 in SEPT9-knockdown MCF-7 cells promoted cell migration, FA maturation and relevant protein expression. [Cell Death Dis] Full Article

The Pharmalogical Reactivation of p53 Function Improves Breast Tumor Cell Lysis by Granzyme B and NK cells through Induction of Autophagy

Researchers showed that the pharmalogical reactivation of a wild type-like p53 function in p53-mutated breast cancer cells using the small molecule CP-31398 increased their sensitivity to natural killer (NK)-mediated lysis. [Cell Death Dis] Full Article

COTI-2 Reactivates Mutant p53 and Inhibits Growth of Triple-Negative Breast Cancer Cells

Using a panel of 18 breast cell lines, investigators carried out MTT assay. p53 protein folding was determined by immunofluorescent staining with the p53 mutant-specific antibody PAb240 and the p53 WT-specific PAb1620. [Breast Cancer Res Treat] Abstract

Integrated Network Analysis Identifies hsa-miR-4756-3p as a Regulator of FOXM1 in Triple Negative Breast Cancer

Researchers applied a master regulator analysis algorithm and confirmed hsa-miR-4756-3p as a candidate miRNA in triple negative breast cancer (TNBC) patients; hsa-miR-4756-3p could regulate TNBC cell line apoptosis, proliferation, migration, and cell cycle as well as suppress TGF-β1 signaling and tumor growth. [Sci Rep] Full Article

Quantitative Proteomic Analysis of Enhanced Cellular Effects of Electrochemotherapy with Cisplatin in Triple-Negative Breast Cancer Cells

Label-free quantitative proteomics was utilized to gain insight into the anticancer mechanisms of electrochemotherapy using electrical pulses and cisplatin on MDA-MB-231, human triple negative breast cancer cells. [Sci Rep] Full Article

Subscribe to one of our other 19 science newsletters such as Prostate Cell News & ESC & iPSC News.

HER2-Targeted Therapies — A Role beyond Breast Cancer

The authors describe the current role of HER2-targeted therapies beyond breast cancer and also highlight the potential of novel HER2-targeted agents that are currently in clinical development. [Nat Rev Clin Oncol] Abstract

Visit our reviews page to see a complete list of reviews in the mammary cell research field.

Clovis Oncology Acquires Rights to FAP-Targeted Radiopharmaceutical Program from 3B Pharmaceuticals

Clovis Oncology, Inc. has entered into a global licensing and collaboration agreement with 3B Pharmaceuticals GmbH, a private German biotechnology company developing targeted radiopharmaceutical drugs and diagnostics for oncology indications with a high unmet medical need. [Clovis Oncology, Inc.] Press Release

Celsius Therapeutics Signs Multiple Agreements with Academic Institutions to Access Samples for the Identification of Novel Targets in Immune Checkpoint Therapy Resistance

Celsius Therapeutics announced the signing of collaboration agreements with the Parker Institute for Cancer Immunotherapy, Institut Gustave Roussy and the University Health Network. [Celsius Therapeutics] Press Release

How US Sanctions Are Crippling Science in Iran

After almost a year of sanctions put in place by US President Donald Trump, Iran is experiencing economic recession, a depreciating currency and high inflation. All of this is stretching budgets for equipment, supplies and travel, endangering research projects and sapping morale, say researchers. [Nature News] Editorial

The Potent Effects of Japan’s Stem-Cell Policies

A five-year regulatory free-for-all in regenerative medicine has given the industry a boost. But patients might be paying the price. [Nature News] Editorial

NEW Gene Regulation: From Mechanisms to Disease
January 26-30, 2020
Keystone, Colorado, United States

Visit our events page to see a complete list of events in the community.

NEW Postdoctoral Position – Cancer Biology (Memorial Sloan Kettering Cancer Center)

Research Scientist – Breast Cancer (The University of Pittsburgh)

Postdoctoral Researcher – Nanomedicine and Immunoengineering (University of California San Diego)

Postdoctoral Research Fellow – Epithelial Growth in Development and Cancer (Fred Hutchinson Cancer Research Center)

Project Scientist – Breast and Hematological Tumors (Cedars-Sinai)

Postdoctoral Research Scientist – Role of Cancer-Associated Fibroblast Metabolism in Breast Cancer (Cancer Research UK Beatson Institute)

Postdoctoral Fellow – Breast and Prostate Cancer (Mayo Clinic Comprehensive Cancer Center)

Research Assistant – Endocrinology in Breast Cancer and Diabetes (Northwell Health)

Bioinformatician – Breast Cancer (Royal College of Surgeons in Ireland)

Postdoctoral Fellow – T-Cell Immunotherapy in Cancers (Memorial Sloan Kettering Cancer Center)

Postdoctoral Associate – Immune Responses (The Jackson Laboratory)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.